Melissa E. Cullom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Melissa E. Cullom has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Allison N. Boyd
Department of Pharmacy, Eskenazi Health , Indianapolis, IN 46202
1 shared publication - Amanda L. Amin
Case Western Reserve University School of Medicine, Case Western Reserve University, Cleveland, OH, United States; University Hospitals Research in Surgical Outcomes and Effectiveness (UH-RISES), University Hospitals Cleveland Medical Center, Cleveland, OH, United States; Division of Surgical Oncology, Department of Surgery, University Hospitals Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, United States
1 shared publication - Anthony J. Archual
Indiana University School of Medicine, Indianapolis, USA
1 shared publication - Ashlie A. Elver
Department of Plastic Surgery, University of Kansas Medical Center, Kansas City, Kansas
1 shared publication - Braden M. Johnson
University of Texas Medical Branch, Department of Plastic Surgery, Galveston, Texas
1 shared publication - Brian M. Christie
Indiana University School of Medicine, Indianapolis, USA
1 shared publication
Latest Publications
- 31 August 2026
- Published by SAGE Publications in HAND
Comparison of Surgeon Expectations to Patient-Reported Outcomes Following Open Carpal Tunnel Release
Background: Open carpal tunnel release (OCTR) is an effective surgical treatment option for carpal tunnel syndrome (CTS). This study evaluates hand surgeon expectations of postoperative recovery versus patient-reported outcomes following OCTR through Patient-Reported Outcomes Measurement Information System (PROMIS) surveys. Methods: Patients who underwent OCTR (Common Procedure Terminology 64721) for CTS performed by 5 hand surgeons were evaluated (2021-2024). PROMIS pain-interference (P-PI) and pain-upper extremity (P-UE) surveys were completed at 2-week, 6-week, and 3-month intervals postoperatively. Patients who underwent simultaneous hand procedures with OCTR and/or had perioperative complications were excluded. Hand surgeons completed PROMIS P-PI and P-UE surveys for theoretical patient groups to predict postoperative recovery in the same timeframe. Higher P-PI scores suggest greater pain, and higher P-UE scores suggest better functionality. Results: Sixty-eight patients were included. Among patients with minimal comorbidities/mild CTS (n = 33), surgeons predicted less pain (P-PI = 38.7 vs 54.8, P = .004) and better functionality (P-UE = 59.8 vs 35.5, P = .00005) compared to mean patient scores at 3 months postoperatively. For patients with multiple comorbidities/mild CTS (n = 17), surgeons predicted less pain (P-PI = 40.7 vs 52.7, P = .013) and better function (P-UE = 53.0 vs 41.3, P = .034) at 3 months postoperatively. In the same cohort, surgeons predicted better function at 2 weeks postoperatively (P-UE = 30.4 vs 36.2, P = .032). For severe CTS patients (n = 18), surgeons predicted less pain (P-PI = 45.6 vs 54.3, P = .009) and better function (P-UE = 37.9 vs 28.5, P = .047) at 6 weeks postoperatively. Conclusions: Hand surgeons may be overly optimistic about recovery timelines for patients undergoing OCTR, specifically underestimating how pain may interfere with daily tasks and their upper-extremity function at 3 months postoperatively.
- 31 August 2026
- Published by SAGE Publications in HAND
Comparison of Surgeon Expectations to Patient-Reported Outcomes Following Open Carpal Tunnel Release
Background: Open carpal tunnel release (OCTR) is an effective surgical treatment option for carpal tunnel syndrome (CTS). This study evaluates hand surgeon expectations of postoperative recovery versus patient-reported outcomes following OCTR through Patient-Reported Outcomes Measurement Information System (PROMIS) surveys. Methods: Patients who underwent OCTR (Common Procedure Terminology 64721) for CTS performed by 5 hand surgeons were evaluated (2021-2024). PROMIS pain-interference (P-PI) and pain-upper extremity (P-UE) surveys were completed at 2-week, 6-week, and 3-month intervals postoperatively. Patients who underwent simultaneous hand procedures with OCTR and/or had perioperative complications were excluded. Hand surgeons completed PROMIS P-PI and P-UE surveys for theoretical patient groups to predict postoperative recovery in the same timeframe. Higher P-PI scores suggest greater pain, and higher P-UE scores suggest better functionality. Results: Sixty-eight patients were included. Among patients with minimal comorbidities/mild CTS (n = 33), surgeons predicted less pain (P-PI = 38.7 vs 54.8, P = .004) and better functionality (P-UE = 59.8 vs 35.5, P = .00005) compared to mean patient scores at 3 months postoperatively. For patients with multiple comorbidities/mild CTS (n = 17), surgeons predicted less pain (P-PI = 40.7 vs 52.7, P = .013) and better function (P-UE = 53.0 vs 41.3, P = .034) at 3 months postoperatively. In the same cohort, surgeons predicted better function at 2 weeks postoperatively (P-UE = 30.4 vs 36.2, P = .032). For severe CTS patients (n = 18), surgeons predicted less pain (P-PI = 45.6 vs 54.3, P = .009) and better function (P-UE = 37.9 vs 28.5, P = .047) at 6 weeks postoperatively. Conclusions: Hand surgeons may be overly optimistic about recovery timelines for patients undergoing OCTR, specifically underestimating how pain may interfere with daily tasks and their upper-extremity function at 3 months postoperatively.
- 15 January 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Intrathecal Baclofen Pump Wean and Risk of Exposure in a Large Total Body Surface Area Burn Wound Patient: A Case Report
Burn injuries in patients with significant preexisting medical conditions provide unique challenges in both medical management and surgical planning. Spasticity, if left untreated, can be one of the most disabling consequences of a neurologic injury. Treatment is largely dependent on pharmacologic management with antispasmodic agents such as baclofen. Baclofen’s effectiveness when taken orally is often limited by its systemic side effects, which mostly affect the CNS. Intrathecal baclofen (ITB) can circumvent these intolerable adverse effects while achieving symptom relief via a more targeted therapeutic route. However, abrupt cessation of chronic baclofen use can precipitate an acute life-threatening withdrawal syndrome. We present a case of a 47-year-old female who sustained 54% TBSA full-thickness flame burns to the circumferential bilateral lower extremities, left arm, left anterior and posterior trunk, flank, and perineum. She had a premorbid C5 spinal cord injury resulting in spastic paraplegia for which she had an ITB pump implanted into her left abdominal wall for symptom management. This pump was directly beneath her operative burn wounds. We discuss the complex issues that were encountered throughout her care related to medication reservoir supply, life-threatening risk of baclofen withdrawal, pain-specialist availability, medical-legal barriers, and the multi-staged surgical plan for coverage, balancing proper wound debridement with risk of device exposure and infection. To our knowledge, this is the only case report detailing the cohort of obstacles that may be associated with these devices, specifically with burn patients.
- 15 January 2025
- Published by Oxford University Press (OUP) in Journal of Burn Care & Research
Intrathecal Baclofen Pump Wean and Risk of Exposure in a Large Total Body Surface Area Burn Wound Patient: A Case Report
Burn injuries in patients with significant preexisting medical conditions provide unique challenges in both medical management and surgical planning. Spasticity, if left untreated, can be one of the most disabling consequences of a neurologic injury. Treatment is largely dependent on pharmacologic management with antispasmodic agents such as baclofen. Baclofen’s effectiveness when taken orally is often limited by its systemic side effects, which mostly affect the CNS. Intrathecal baclofen (ITB) can circumvent these intolerable adverse effects while achieving symptom relief via a more targeted therapeutic route. However, abrupt cessation of chronic baclofen use can precipitate an acute life-threatening withdrawal syndrome. We present a case of a 47-year-old female who sustained 54% TBSA full-thickness flame burns to the circumferential bilateral lower extremities, left arm, left anterior and posterior trunk, flank, and perineum. She had a premorbid C5 spinal cord injury resulting in spastic paraplegia for which she had an ITB pump implanted into her left abdominal wall for symptom management. This pump was directly beneath her operative burn wounds. We discuss the complex issues that were encountered throughout her care related to medication reservoir supply, life-threatening risk of baclofen withdrawal, pain-specialist availability, medical-legal barriers, and the multi-staged surgical plan for coverage, balancing proper wound debridement with risk of device exposure and infection. To our knowledge, this is the only case report detailing the cohort of obstacles that may be associated with these devices, specifically with burn patients.
- 8 October 2022
- Published by Elsevier in Journal of Surgical Education
- Vol. 80 (1) , 1-6
Implementation of a Near-Peer Surgical Anatomy Teaching Program into the Surgery Clerkship
- 8 October 2022
- Published by Elsevier in Journal of Surgical Education
- Vol. 80 (1) , 1-6
Implementation of a Near-Peer Surgical Anatomy Teaching Program into the Surgery Clerkship
- 3 March 2022
- Published by Wiley in Microsurgery
- Vol. 43 (1) , 57-62
Comparing tissue oximetry to doppler monitoring in 1367 consecutive breast free flaps
Background: Retrospective studies evaluating tissue oximetry in a more recent cohort have shown superiority in flap outcomes. This study compares the use of tissue oximetry in a historical cohort to clinical observation and handheld doppler in a more recent cohort. We hypothesize that there is no benefit to using tissue oximetry.Methods: A retrospective review was performed on patients who underwent abdominal‐based autologous breast reconstruction by five microsurgeons at an academic institution from 2009 to 2020. Method of postoperative flap monitoring was determined then operative details and complications were analyzed.Results: 1367 flaps were reviewed; 740 flaps in 460 patients were monitored with clinical observation and tissue oximetry, and 627 flaps in 391 patients were monitored with clinical observation and handheld doppler. There were no statistical differences in ischemic (p = .59) or congestive complications (p = .41), flap salvage rates when exploring for venous or arterial compromise (p = .52), or early flap loss (p = .56). Although not significant, acute flap‐related return to the operating room was lower in the doppler group (4.6%) compared to the oximetry group (6.1%; p = .22). Flaps monitored with tissue oximetry had a statistical increase in length of stay (4.8 ± 1.4 days vs. 3.8 ± 1.6 days; p ≤ .001). The rates of late partial flap loss and fat necrosis were significantly higher in the oximetry group (2.6%, 19/740 vs. 0.3%, 2/740; p = .04) and (18.2%, 135/740 vs. 13.6%, 85/627; p = .02), respectively.Conclusions: There is no statistical benefit to the use of tissue oximetry compared to handheld doppler in flap monitoring with regards to flap outcomes.
- 3 March 2022
- Published by Wiley in Microsurgery
- Vol. 43 (1) , 57-62
Comparing tissue oximetry to doppler monitoring in 1367 consecutive breast free flaps
Background: Retrospective studies evaluating tissue oximetry in a more recent cohort have shown superiority in flap outcomes. This study compares the use of tissue oximetry in a historical cohort to clinical observation and handheld doppler in a more recent cohort. We hypothesize that there is no benefit to using tissue oximetry.Methods: A retrospective review was performed on patients who underwent abdominal‐based autologous breast reconstruction by five microsurgeons at an academic institution from 2009 to 2020. Method of postoperative flap monitoring was determined then operative details and complications were analyzed.Results: 1367 flaps were reviewed; 740 flaps in 460 patients were monitored with clinical observation and tissue oximetry, and 627 flaps in 391 patients were monitored with clinical observation and handheld doppler. There were no statistical differences in ischemic (p = .59) or congestive complications (p = .41), flap salvage rates when exploring for venous or arterial compromise (p = .52), or early flap loss (p = .56). Although not significant, acute flap‐related return to the operating room was lower in the doppler group (4.6%) compared to the oximetry group (6.1%; p = .22). Flaps monitored with tissue oximetry had a statistical increase in length of stay (4.8 ± 1.4 days vs. 3.8 ± 1.6 days; p ≤ .001). The rates of late partial flap loss and fat necrosis were significantly higher in the oximetry group (2.6%, 19/740 vs. 0.3%, 2/740; p = .04) and (18.2%, 135/740 vs. 13.6%, 85/627; p = .02), respectively.Conclusions: There is no statistical benefit to the use of tissue oximetry compared to handheld doppler in flap monitoring with regards to flap outcomes.
- 1 November 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (5) , 1225-1229
Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant chemotherapy
- 1 November 2020
- Published by Elsevier in The American Journal of Surgery
- Vol. 220 (5) , 1225-1229
Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant chemotherapy